• **Name:** Louis M. Staudt
• **Affiliation/Current Position:**
Director, Center for Cancer Genomics, National Cancer Institute
Chief, Lymphoid Malignancies Branch, National Cancer Institute
• **Country:** USA
• **ICKSH2022 Presentation Title:**
Rational development of targeted therapies to cure molecular subtypes of DLBCL
• **Educational Background:**
M.D. University of Pennsylvania School of Medicine, 1982
Ph.D., Immunology, University of Pennsylvania School of Medicine, 1982
B.A., Harvard College, Biochemistry, Cum Laude, 1976
• **Professional Experiences:**

| | |
|---|---|
| 1982 – 1983 | Postdoctoral Fellow, Wistar Institute, Philadelphia, PA (Laboratory of Walter Gerhard) |
| 1983 – 1984 | Intern, Internal Medicine, Presbyterian - Univ. of Pennsylvania Medical Center, Philadelphia, Pennsylvania |
| 1984 – 1988 | Postdoctoral Fellow, Whitehead Institute, Cambridge, MA (Laboratory of David Baltimore) |
| 1988 – 1995 | Senior Staff Fellow, Metabolism Branch, National Cancer Institute, NIH |
| 1995 – 2001 | Senior Investigator, Metabolism Branch, National Cancer Institute, NIH |
| 2001 – 2013 | Chief, Lymphoid Malignancies Section, Metabolism Branch, National Cancer Institute, NIH |
| 2003 – present | Adjunct Professor, University of Pennsylvania School of Medicine, Philadelphia, PA |
| 2004 – 2013 | Deputy Chief, Metabolism Branch, National Cancer Institute, NIH |
| 2013 – present | Chief, Lymphoid Malignancies Branch, National Cancer Institute, NIH |
| 2013 – present | Director, Center for Cancer Genomics, National Cancer Institute, NIH |

• **Professional Organizations**
National Academy of Sciences
National Academy of Medicine
Fellow of the AACR Academy, American Association for Cancer Research
• **Main Scientific Publications:**

1. Alizadeh A, Eisen M, Brown PO, Staudt LM et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 403:503-511.
2. Rosenwald A, Wright G, Staudt LM et al. The use of molecular profiling to predict survival after chemotherapy of diffuse large B-cell lymphoma. N Engl J Med 346:1937-1947.
3. Lenz G, Wright G, Staudt LM et al. Stromal gene signatures in large-B-cell lymphomas. New Engl J Med 2008 359:2313-23.
4. Davis RE, Ngo, VN, Lenz G, Staudt LM et al. Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma. Nature 2010 463:88-92.
5. Ngo VN, Young RM, Staudt LM et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011 470:115-119.
6. Wilson WH, Young RM, Staudt LM et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature Medicine 2015 21:922-6.
7. Lionakis MS, Dunleavy K, Roschewski M, Staudt LM*, Wilson WH* et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 2017 31:833-843. *co-senior authors.
8. Schmitz R, Wright GW, Huang DW, Johnson CA, Staudt LM et al. Genetics and pathogenesis of diffuse large B cell lymphoma. N Engl J Med 2018 378:1396-1407.
9. Phelan JD, Young RM, Oellerich T*, Staudt LM* et al. A multiprotein supercomplex controlling oncogenic signaling in lymphoma. Nature 2018 560:387-391. *co-senior authors.
10. Wright G, Staudt LM et al. A probabilistic classification tool for diffuse large B-cell lymphoma genetic subtypes with therapeutic implications. Cancer Cell 2020 37:551-568.
11. Wilson WH, Wright G, Staudt LM et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell 2021, in press.